Elevated C-reactive protein levels during first trimester of pregnancy are indicative of preeclampsia and intrauterine growth restriction
Introduction
Common pregnancy disorders include hypertensive disorders of pregnancy, gestational diabetes, and premature birth. Maternal health is especially affected when preeclampsia or more severe complications such as eclampsia or HELLP develop. These syndromes substantially contribute to maternal morbidity and mortality. Symptoms of preeclampsia include hypertension and proteinuria, and preeclampsia are associated with general endothelial dysfunction (Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy, 2000). Preeclampsia is associated with an increased risk of intrauterine growth restriction (IUGR), although most preeclamptic patients do not give birth to a growth-restricted baby (Xiong et al., 1999).
In recent years, much focus has been put on the detection of pregnancy disorders before the symptoms actually occur. Both preeclampsia and IUGR share similar defects in placental development and function. Besides a shallow trophoblast invasion leading to poor placental perfusion (Meekins et al., 1994, Sheppard and Bonnar, 1981), preeclampsia and IUGR are also associated with high levels of apoptosis in the placenta (Erel et al., 2001, Leung et al., 2001). At present, Doppler analysis at the 24th week of pregnancy, or screening of circulating pregnancy-associated proteins in maternal plasma or serum, can be used to indicate which women are at risk to develop maternal-fetal pathologies such as preeclampsia or IUGR (Chien et al., 2000, Reis et al., 2002, Zimmermann et al., 1997). Circulating markers potentially useful in early pregnancy, i.e. at the presymptomatic stage, share a restricted but common feature indicative of placental production and function.
In this respect, C-reactive protein (CRP), being a sensitive marker of tissue damage and inflammation, can be a potential marker. Plasma CRP levels rise in cases of acute infection, malignancy, and inflammatory diseases. CRP can bind to chromatin, released from apoptotic or necrotic cells, and to small nuclear ribonucleoprotein particles. It has been proposed that CRP acts as a scavenger and is responsible for the clearance of membranes and nuclear antigens (DuClos, 1996). It has been suggested that CRP, in accordance with its proposed function, may play a role in eliciting the inflammatory response characteristics of preeclampsia (Redman et al., 1999). Recently, it has been demonstrated that CRP enhanced opsonization, and phagocytosis of apoptotic cells is specific for and restricted to apoptotic cells. Once cells have become necrotic, the effect of CRP is lacking (Gershov et al., 2000). CRP is elevated in women with overt preeclampsia (Teran et al., 2001), but there is still debate about its potential use as an early marker for preeclampsia. Wolf et al. (2001) showed elevated CRP levels during the first trimester in women who subsequently develop preeclampsia, whereas Savvidou et al. (2002) showed that late second trimester CRP levels were not associated with preeclampsia. In this study, we investigated whether CRP levels are elevated during the first trimester in women from a low-risk population who subsequently develop preeclampsia or deliver a growth-restricted baby.
Section snippets
Materials and methods
Pregnant women referred to the Department of Obstetrics and Gynecology at the VU University Medical Center were asked to participate in this study to investigate the possible use of CRP as a marker for preeclampsia or IUGR. The study was approved by the Medical Ethics Committee of the Hospital. Women were randomly enrolled and written informed consent was obtained during their first antenatal visit. During this visit, blood samples were withdrawn from the study participants for CRP analysis.
Results
CRP levels were measured in 107 pregnant women between weeks 10 and 14 of gestation. Six women developed preeclampsia (5.6%), and nine women gave birth to a growth-restricted baby (8.4%). Ninety-two women had an uneventful pregnancy and gave birth to appropriate-for-gestational age babies (86.0%). Table 1 shows the population characteristics of the three main study groups. As expected, highest diastolic blood pressure readings in the preeclampsia group were significantly elevated compared to
Discussion
The aim of this study was to investigate whether CRP levels are elevated between 10 and 14 weeks of pregnancy in women who subsequently developed preeclampsia or delivered a growth-restricted baby. Indeed, during this timeframe of pregnancy, mean CRP values are significantly elevated in women from the preeclampsia and IUGR study groups when individually matched to women from the control group (P=0.031 and P=0.041, respectively). Power calculations confirmed the validity of the results obtained.
Acknowledgements
This study was financially supported by the ZON/Praeventiefonds, grant number 28-3022. We would like to thank T. Noviemoibra, MD, of the Department of Obstetrics and Gynecology at the VU University Medical Center for her contribution in studying the variation in CRP levels in women referred to the clinic for prenatal diagnosis. We would also like to thank Astrid Kok and Hetty Leeuwestein for their aid with the CRP measurements.
References (17)
- et al.
Apoptosis in the placenta of pregnancies complicated with IUGR
Int. J. Gynaecol. Obstet.
(2001) - et al.
Increased placental apoptosis in pregnancies complicated by preeclampsia
Am. J. Obstet. Gynecol.
(2001) - et al.
Preeclampsia: an excessive maternal inflammatory response to pregnancy
Am. J. Obstet. Gynecol.
(1999) - et al.
Levels of C-reactive protein in pregnant women who subsequently develop pre-eclampsia
Br. J. Obstet. Gynaecol.
(2002) - et al.
Elevated C-reactive protein and pro-inflammatory cytokines in Andean women with pre-eclampsia
Int. J. Gynaecol. Obstet.
(2001) - et al.
Plasma placenta growth factor levels in midtrimester pregnancies
Obstet. Gynecol.
(2001) - et al.
Obesity and preeclampsia: the potential role of inflammation
Obstet. Gynecol.
(2001) - et al.
Impact of pregnancy-induced hypertension on fetal growth
Am. J. Obstet. Gynecol.
(1999)
Cited by (170)
Urinary phenol and paraben concentrations in association with markers of inflammation during pregnancy in Puerto Rico
2024, Science of the Total EnvironmentInflammatory markers in serum and placenta in a randomized controlled trial of group prenatal care
2023, American Journal of Obstetrics and Gynecology MFMMaternal plasma transforming growth factor-β1 (TGF-β1) and newborn size: the Araraquara Cohort Study
2023, Jornal de PediatriaProinflammatory changes in the maternal circulation, maternal–fetal interface, and placental transcriptome in preterm birth
2023, American Journal of Obstetrics and GynecologyHigh-sensitivity C-reactive protein use in cardiovascular risk screening at 6 to 12 months postpartum following hypertensive disorders of pregnancy
2023, American Journal of Obstetrics and Gynecology MFMAssociations of urinary phthalate metabolites and inflammatory biomarkers among pregnant women in Puerto Rico
2023, Science of the Total Environment